TMS Therapy · Hayward, CA

Your psychiatrist has just told you that you’d be a good candidate for TMS. You read the clinic’s page. You looked at the testimonials. For the first time in months you feel something close to hope. Then the front desk asks for your insurance card and adds, almost as an afterthought, “Let me check what your plan needs before we get you on the schedule.”

That’s the moment most California patients meet the real second half of TMS care. The clinical decision is yours and your provider’s. The financial one belongs to a utilization-review nurse you’ll never meet, working off a checklist you’ve never seen, applying medical-necessity criteria written into your plan’s policy manual.

The good news is that in California, the legal architecture around mental-health coverage is one of the strongest in the country. The catch is that strong protections are not the same thing as automatic approval. This is what coverage actually looks like, what your plan is allowed to require, and what California’s parity law does — and does not — do for you.

The short answer

In California, most commercial insurance plans cover TMS when three conditions are met: you have a diagnosis of major depressive disorder, you have tried and not responded adequately to antidepressant medication, and your provider can document that TMS is medically necessary using accepted clinical standards. Medi-Cal added a TMS coverage pathway on August 1, 2024, with prior authorization required.^[1] Medicare has covered TMS for treatment-resistant depression since 2012.

So coverage is the rule, not the exception. The variable is the paperwork. Almost every plan in California requires prior authorization before your first session, and the approval depends on whether your file demonstrates what the plan considers medical necessity. Sloppy or incomplete submissions account for the majority of first-pass denials I see in practice.

What California parity law actually does

The California Mental Health Parity Act lives at Health & Safety Code § 1374.72 for state-regulated health plans and Insurance Code § 10144.5 for state-regulated insurers. The original 1999 statute required plans to cover nine listed severe mental illnesses, major depression among them, on terms comparable to medical and surgical care.^[2]

In 2020, Senate Bill 855 rewrote and significantly expanded that statute. As of January 1, 2021, every California state-regulated health plan must cover medically necessary treatment for any mental health or substance use disorder listed in the current edition of the DSM or the mental and behavioral disorders chapter of the ICD, under the same terms and conditions applied to other medical conditions.^[3] Major depressive disorder qualifies. So does generalized anxiety disorder, OCD, PTSD, ADHD, bipolar disorder, and substance use disorders.

SB 855 also added Section 1374.721, which requires plans to base medical-necessity determinations and utilization-review criteria on generally accepted standards of mental health and substance use disorder care.^[3] This is the language that matters most for TMS appeals. It means the plan cannot invent its own coverage criteria that are stricter than what mainstream psychiatric practice considers appropriate. Plans must rely on evidence-based clinical guidelines developed by independent nonprofit professional organizations.

What parity law does not do is skip the approval process. Your plan can still require prior authorization. It can still require documentation. It can still apply utilization-review criteria. What it cannot do is hold mental health care to a stricter standard than it would apply to comparable medical or surgical care, or substitute its own commercial criteria for the consensus standards of the field.

What plans actually ask for

A TMS prior-authorization submission for major depressive disorder typically includes:

Your diagnosis, documented with an ICD-10 code (F32.x for single episode, F33.x for recurrent) and a structured severity measure such as the PHQ-9 or MADRS. Most plans want a PHQ-9 score of 15 or above, or the MADRS equivalent.^[4]

Your medication history. Plans want specific drug names, dates, maximum dose, time at that dose, and the reason each trial ended. Most California commercial plans require evidence of at least two adequate antidepressant trials, from different classes, that either failed to produce adequate response or caused intolerable side effects. “An SSRI” is not enough — they want “sertraline 200 mg daily from June through October 2024, discontinued due to no response.”^[5]

Your therapy history. Most plans want documentation that you have completed an adequate trial of evidence-based psychotherapy — usually CBT, behavioral activation, or interpersonal therapy — or that it is contraindicated or unavailable in your area.^[4]

Your treatment plan. The submission must specify that your provider intends to deliver TMS using an FDA-cleared device for major depressive disorder. The original FDA clearance was granted to the NeuroStar system in October 2008, based on the pivotal multisite randomized trial by O’Reardon and colleagues.^[6] Several other devices have since received clearance, and most commercial plans will cover any FDA-cleared system if the protocol matches the indication.

The absence of contraindications. No personal history of seizure disorder (relative, not absolute), no ferromagnetic implants near the head, no cardiac pacemakers or implanted neurostimulators, no active substance intoxication. Pregnancy gets reviewed separately.

What’s most likely to get covered — and what isn’t

Coverage is strongest, by a wide margin, for major depressive disorder in adults who have not responded adequately to medication. This is the indication TMS was originally cleared for in 2008, the indication with the largest body of randomized-controlled-trial evidence, and the one every major commercial plan in California recognizes.^[6][7] The American Psychiatric Association’s consensus recommendations and large naturalistic studies in U.S. clinical practice both support TMS as an appropriate option for patients who have not responded to one or more antidepressant trials.^[7][8]

OCD has its own FDA clearance (Deep TMS, 2018) and increasing coverage acceptance, though it usually requires documentation of failed SSRI trials and a course of exposure-and-response prevention therapy.

Anxious depression (a comorbid presentation common in TRD) is generally covered under the MDD indication. Generalized anxiety disorder as a standalone indication is harder — Deep TMS received a separate clearance for anxious depression in 2021, but coverage policies vary widely by plan.

PTSD, ADHD, and other off-label indications usually require additional documentation, a peer-to-peer review with the plan’s medical director, and sometimes a written letter of medical necessity that cites the specific clinical evidence supporting use in your case. Some plans approve, many deny on first submission.

The pattern in California is consistent: the closer your case looks to the FDA-cleared MDD indication with adequate medication failure, the smoother the approval. The further you drift from that template, the more documentation you need.

What changed for Medi-Cal in 2024

Until August 2024, TMS coverage for the Medi-Cal population in California was effectively unavailable except through narrow research or county-specific programs. That changed on August 1, 2024, when Medi-Cal added CPT codes 90867, 90868, and 90869 as a covered benefit for patients age 15 and older diagnosed with major depressive disorder.^[1]

The codes correspond to the three stages of a TMS course. 90867 covers the initial session, including cortical mapping, motor-threshold determination, and the first treatment. 90868 covers each subsequent treatment session — the bulk of the 36-session course. 90869 covers motor-threshold recalculation when the patient’s clinical situation requires re-mapping mid-course.^[1]

A Treatment Authorization Request (TAR) is required before initiating treatment. The clinical criteria mirror commercial-plan requirements — DSM-confirmed MDD, documented failure of antidepressant medication, no absolute TMS contraindication. The practical implication: a substantial population of California patients who previously had no realistic path to TMS now do, provided their provider can navigate the TAR submission.

What to do if you’re denied

First-pass denials happen, even on strong submissions. The two most common reasons in my practice are insufficient medication-trial documentation (often because a prior provider didn’t note exact doses or time at dose) and insufficient evidence of adequate psychotherapy. Both are usually fixable on appeal.

You have appeal rights at three levels. The first is internal: your plan must reconsider the denial with a different reviewer, typically within thirty days. The second is an independent medical review through the California Department of Managed Health Care (for HMO and most PPO plans regulated by DMHC) or the California Department of Insurance (for plans regulated by CDI). Independent medical review is free, binding on the plan, and routinely overturns denials when the underlying clinical case is strong.

The third level — relevant for self-funded employer plans regulated under ERISA rather than California law — is the federal Mental Health Parity and Addiction Equity Act framework. The landmark case here is Wit v. United Behavioral Health. In 2019, the U.S. District Court for the Northern District of California found that United had applied medical-necessity criteria for behavioral-health claims that deviated from generally accepted standards of care, and ordered the plan to reprocess tens of thousands of denied claims.^[9] The Ninth Circuit narrowed parts of the ruling on appeal in 2022 and reissued the opinion in January 2023, but the broader point survives: insurers cannot quietly substitute commercially convenient coverage criteria for the standards of mainstream clinical practice.^[9]

The federal MHPAEA framework was further strengthened by the September 2024 Final Rule from the Departments of Labor, Health and Human Services, and Treasury, which clarified that nonquantitative treatment limitations — including prior authorization, network composition, and reimbursement methodology — must be no more restrictive for mental health benefits than for medical and surgical benefits.^[10] Federal enforcement of certain provisions of that rule was paused in May 2025 pending litigation, but the underlying 2013 regulations and the 2021 statutory mandate to maintain written NQTL comparative analyses remain in full force.^[10]

None of this means appeals are automatic wins. They are not. But the architecture exists, and patients who appeal with strong clinical documentation and parity arguments do prevail at meaningful rates.

What unmet need actually looks like

For context on how much coverage friction matters: a 2024 study in Health Affairs Scholar found that among insured U.S. adults with symptoms consistent with moderately severe or severe depression, 32.4 percent had avoided mental health care in the past twelve months because of affordability concerns, and more than half had not seen a mental health specialist.^[11] Insurance coverage alone is necessary but not sufficient. The friction between coverage on paper and access in practice is precisely what parity law is supposed to close. It hasn’t closed it yet, but it has narrowed it considerably for patients who know how to use it.

The literature is also explicit about TMS specifically. A formal policy analysis published in the Journal of ECT in 2013 argued that the case-by-case prior-authorization regime then in place was overly restrictive given the strength of the underlying RCT evidence.^[12] The intervening decade has produced more evidence, more FDA clearances, and gradually more accommodating coverage — but the structural mismatch between what the science supports and what payer policy allows has not fully resolved.

What to ask before you start

Five questions for your clinic before you commit to a course:

“Has my benefits check been completed, and what did it find?” A real benefits check is more than a phone call to verify the policy is active. It confirms whether TMS is a covered benefit on your specific plan, whether prior authorization is required, and what your financial responsibility will be after deductible, copay, and coinsurance.

“What medication trials does my plan require, and do mine qualify?” If you’ve tried three antidepressants but only one was at adequate dose for adequate duration, you may not meet criteria. The clinic should look at this before submitting.

“What’s your prior-authorization first-pass approval rate, and what happens if mine gets denied?” A clinic that does this work routinely should have data on this and a clear appeal process. If they don’t, you may be the first patient bearing the cost of their learning curve.

“Is the device and protocol the clinic uses covered for my diagnosis?” FDA-cleared TMS systems differ. NeuroStar, Magstim, MagVenture, Brainsway Deep TMS, and others have different clearances. Most plans cover any FDA-cleared system for the cleared indication, but it’s worth verifying for your specific plan and diagnosis.

“What will I actually owe?” Coinsurance on a 36-session TMS course can vary from a few hundred dollars to several thousand depending on your plan structure. You should have this number in writing before session one.

The bottom line

Insurance covers TMS in California more often than not, especially for major depressive disorder in patients who have tried and not responded to antidepressant medication. The California Mental Health Parity Act and federal MHPAEA give you real legal protection against arbitrary denials. Medi-Cal opened a pathway in August 2024. None of this makes the paperwork disappear.

The clinics that get patients onto treatment fastest are the ones that treat the benefits check and the prior authorization as part of the clinical workflow, not as an afterthought. If your file is clean and your case is solid, approval is usually a matter of days to a couple of weeks. If it’s denied, the appeal process is real and it favors patients with documented clinical need.

Coverage shouldn’t be the reason you don’t try TMS. The law is on your side. The work is in the file.

By Nefretiri Abat, JD, PMHNP-BC — Founder, Exxceed Wellness, Hayward CA. This article is for general education and does not substitute for individualized medical advice.